Satellos Bioscience Granted Composition of Matter Patent for Forazapadin by USPTO
MT newswire2026/10/05 13:3409:34 AM EDT, 10/05/2026 (MT Newswires) -- Satellos Bioscience (MSCL.TO, MSLE) was granted US Patent No. 12,747,245, entitled "AP2 associated kinase 1 inhibitors and uses thereof," by the United States Patent and Trademark Office (USPTO), it said Monday. The US patent includes composition of matter claims covering forazapadin, the company's lead clinical-stage drug candidate, and a broader class of AAK1 inhibitors and related compounds within Satellos' muscle-regeneration platform. The composition of matter provides US intellectual property protection through Sept. 6, 2044, as forazapadin advances in Phase 2 development, it added. "As the strongest form of patent protection for a pharmaceutical product, this patent reinforces the novelty of our approach to restoring muscle regeneration and strengthens our intellectual property (IP) estate surrounding forazapadin," chief executive Frank Gleeson said. Shares of the company closed unchanged at CA$12.01 Friday on the Toronto Stock Exchange.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
